Home » Topics » Regulatory » EMA

EMA
RSS

Defibrotide receives positive COMP opinion for prevention of GVHD

Oct. 14, 2013

FDA and EMA accept OMS-302 marketing applications for review

Oct. 3, 2013

MAA filing for naloxegol for opioid-induced constipation accepted by EMA

Sep. 30, 2013

EMA accepts olaparib MAA for review

Sep. 30, 2013

EMA committee recommends approval of Cimzia in new indication

Sep. 25, 2013

CHMP issues positive opinion for PSD-502 in premature ejaculation

Sep. 25, 2013

Kineret receives positive CHMP opinion for cryopyrin-associated periodic syndromes

Sep. 25, 2013

EMA committee recommends approval of Xofigo injection for CRPC

Sep. 23, 2013

Trastuzumab emtansine receives committee recommendation in E.U.

Sep. 23, 2013

CHMP recommends E.U. approval of canagliflozin

Sep. 23, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...